Investigating how autoantibodies affect blood transfusion responses in sickle cell disease
Autoantibody-induced type 1 interferons and RBC alloimmunization in sickle cell disease
This study is looking into why people with sickle cell disease are more likely to develop complications from blood transfusions and aims to find ways to make transfusions safer for them by understanding their immune responses better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10884195 on NIH RePORTER |
What this research studies
This research focuses on understanding why patients with sickle cell disease (SCD) have a higher rate of red blood cell (RBC) alloimmunization, which can lead to serious complications during blood transfusions. The study aims to identify specific factors, including the role of type 1 interferons and autoantibodies, that contribute to this increased risk. By analyzing the immune responses and genetic signatures of SCD patients, the researchers hope to develop personalized transfusion protocols that could improve patient outcomes. The methodology involves examining immune responses and signaling pathways related to inflammation and autoimmunity in these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sickle cell disease who have experienced or are at risk of RBC alloimmunization.
Not a fit: Patients without sickle cell disease or those who have not undergone blood transfusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer blood transfusion practices for patients with sickle cell disease, reducing the risk of severe hemolytic reactions.
How similar studies have performed: Previous research has indicated that understanding immune responses in transfusion settings can lead to improved patient care, suggesting potential success for this approach.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Gibb, David R — Cedars-Sinai Medical Center
- Study coordinator: Gibb, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.